drugset / Trial / NCT00425919

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

NCT00425919 ↗

Phase 2 Terminated 500 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

Timeline

Start
2007-01
Primary completion
—
Completion
2007-10

Outcome

Outcome not reported

Stopped: “Study terminated as a result of interim analysis not meeting predetermined criteria.”

Drugs

EvaluationDrugModalityDoseRoute
Subject INDEGLITAZAR Small molecule — —